Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
Guru
G
Sonpavde
Jonathan E
JE
Rosenberg
Noah M
NM
Hahn
Matthew D
MD
Galsky
Rick
R
Bangs
Cora N
CN
Sternberg
Nicholas J
NJ
Vogelzang
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary; D017277:Drug Approval; D019317:Evidence-Based Medicine; D006801:Humans; D017671:Platinum Compounds / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D017671:Platinum Compounds; C111217:vinflunine; D014747:Vinblastine